Group 1 - The genetically modified (GM) concept sector declined by 0.17% as of the market close on September 29, ranking among the top decliners in concept sectors [1] - Within the GM sector, notable decliners included Jincheng Pharmaceutical, Shennong Agriculture, and Guotou Fengle, while the top gainers were Xin'an Co., Huabang Health, and Top Cloud Agriculture, with respective increases of 3.89%, 1.80%, and 0.78% [1] - The GM sector experienced a net outflow of 80 million yuan in principal funds today, with Jincheng Pharmaceutical leading the outflow at 39.04 million yuan [2] Group 2 - The top stocks with net outflows in the GM sector included Longping High-Tech, Xin'an Co., and Nongfa Seed Industry, with outflows of 13.57 million yuan, 11.01 million yuan, and 8.06 million yuan respectively [2] - Conversely, the stocks with the highest net inflows included Dabeinong, KQ Bio, and Dunhuang Seed Industry, with inflows of 12.52 million yuan, 2.55 million yuan, and 2.35 million yuan respectively [2][3] - The trading performance of Jincheng Pharmaceutical showed a decline of 4.49% with a turnover rate of 4.06% [2]

Core Insights - The vitamin sector experienced a decline of 0.18% as of the market close on September 29, with *ST Suwu hitting the daily limit down, while stocks like Jilin Aodong, Keyuan Pharmaceutical, and Haixin Co. saw gains of 6.69%, 1.93%, and 1.83% respectively [1][2][3] Market Performance - The vitamin sector ranked among the top decliners, with significant losses observed in stocks such as *ST Suwu (-4.76%), Jincheng Pharmaceutical (-4.49%), and Huaheng Biological (-3.59%) [1][2] - Conversely, Jilin Aodong led the gains in the sector with a notable increase of 6.69%, followed by Keyuan Pharmaceutical and Haixin Co. [1][3] Capital Flow - The vitamin sector saw a net outflow of 374 million yuan, with 54 stocks experiencing net outflows, and 18 stocks seeing outflows exceeding 10 million yuan [1] - The stock with the highest net outflow was Angel Yeast, with 78.26 million yuan, followed by Jincheng Pharmaceutical and New Hecheng with outflows of 39.04 million yuan and 26.95 million yuan respectively [1][2] - In contrast, the stocks with the highest net inflows included Jilin Aodong (106 million yuan), Chuaning Biological (6.01 million yuan), and Shuoshi Biological (5.10 million yuan) [1][3]

Group 1 - The company, Jincheng Pharmaceutical, has submitted a patent application for the preparation method and application of nicotine salt compounds through its subsidiary [1] - The patent application is currently under review [1]

Group 1 - The company Jin Cheng Pharmaceutical reported that as of September 20, 2025, the total number of shareholders is 28,237 [2]

Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiary has received a notification for the approval of the chemical raw material drug, Mirabegron, which is primarily used for treating overactive bladder (OAB) conditions such as urinary incontinence, urgency, and frequency [1] Group 1: Product Approval and Market Impact - Mirabegron is a selective β-3 adrenergic receptor agonist, and its approval indicates compliance with national technical standards for raw material drug review [1] - The approval allows for production and sales in the domestic market, enhancing the company's product line in raw materials and improving its competitiveness in the chemical raw material drug sector [1] Group 2: Market Data and Trends - Currently, there are 18 companies in China with Mirabegron approval status A on the raw material drug registration platform [1] - According to IMS data, global consumption of Mirabegron raw materials is projected to be 57.91 tons in 2022, 63.05 tons in 2023, and 69.79 tons in 2024 [1] - Global sales of Mirabegron formulations are expected to reach $3.286 billion in 2022, $3.420 billion in 2023, and $3.536 billion in 2024 [1]

Core Viewpoint - The company has submitted a patent application for a method and application of nicotine salt compounds, which aims to address the issue of nicotine release not matching human metabolism, particularly the insufficient release in later stages [1] Company Summary - The subsidiary of the company has filed a patent application for the preparation method and application of nicotine salt compounds, which is currently under review [1]

Core Viewpoint - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug Mirabegron [1] Group 1 - The approval notification number is 2025YS00837 [1] - The drug approved is a chemical raw material named Mirabegron [1]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary has received approval for the marketing application of Mirabegron, a selective β-3 adrenergic receptor agonist, which is primarily used to treat overactive bladder (OAB) symptoms such as urinary incontinence, urgency, and frequency [1] Company Summary - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has recently received a notification from the National Medical Products Administration regarding the approval of the marketing application for the chemical raw material drug Mirabegron [1] - Mirabegron is indicated for the treatment of overactive bladder (OAB), addressing conditions like urinary incontinence, urgency, and frequency [1]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) has received approval from the National Medical Products Administration for its chemical raw material drug, Mirabegron, which is a selective β-3 adrenergic receptor agonist used to treat overactive bladder (OAB) symptoms such as urinary incontinence, urgency, and frequency [1] Group 1 - The company’s wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., is responsible for the approval of Mirabegron [1] - Mirabegron is specifically indicated for the treatment of overactive bladder (OAB) [1] - The approval marks a significant milestone for the company in expanding its product portfolio in the pharmaceutical market [1]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the approval notice for the marketing application of the chemical raw material drug Mirabegron from the National Medical Products Administration [1] Group 1 - The chemical raw material drug approved is named Mirabegron, which is a selective β-3 adrenergic receptor agonist [1] - Mirabegron is primarily used for the treatment of overactive bladder (OAB), including symptoms such as urinary incontinence, urgency, and frequency [1]